RE:Investors everytime they see Dan they sellLayth1990 wrote: A smart move is to let someone else be the face of the company(someone from the board). Investors are panicing with his way of communicating and answering the questions. We are numb hearing same sh*t
i am concerned because this can be dragged way down with the taxloss season.
I would agree there was little need for that update - but they did open it up for question submission. It was made available to investors.
The price has everything to do with the time of year and the expected slow developments for the rest of 2021 - CITA being the unknown and a presentation to accompany or follow. Still a lot of confused stock warriers who don't know if chronic pain is dead or alive. The fear of pivoting to acute and what appears to be a "start over."
At some point, investors come back to the store window and buy up cheap shares - they always do.
With a boat-load of cash ... and ... if we're putting acute dosing together ... and ... if we get to P2 in 2022 ... the market will come around.
Then, in later 2022 ... if ATE has a chronic regimen plan to share (as it needs acute development to be part of the chronic regimen understanding and development) - we further move to higher ground.
It's not failure - it's progress forward in H2S understanding. Unfortunately it isn't a path any of us expected or wanted - but it is the path that is needed. All in my opinion.